Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

October 25, 2024

Study Completion Date

October 25, 2024

Conditions
Yellow Fever
Interventions
BIOLOGICAL

Yellow fever vaccine

The yellow fever vaccine (YFV-17D) manufactured by Sanofi Pasteur as a one-dose vial will be purchased from the manufacturer. Vaccine will be stored at the Emory Investigational Drug Service (IDS) between 2 to 8 degrees Celsius as per the manufacturer's instructions. It will be transported to the Hope Clinic per the Standard Operating Procedures.

OTHER

Deuterium (70% enriched 2H2O) labeled water

70% enriched 2H2O will be obtained from Cambridge Isotope Laboratories (Andover, MA) in sterile 1 Liter containers. An Emory Investigational Drug Service (IDS) pharmacist will prepare sterile 50 milliliter aliquots with a tamper seal which will be transported to the Hope Clinic at room temperature.

Trial Locations (1)

30030

The Hope Clinic of Emory Vaccine Center, Decatur

All Listed Sponsors
collaborator

University of California, Berkeley

OTHER

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Sri Edupuganti

OTHER

NCT01290055 - Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine | Biotech Hunter | Biotech Hunter